TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer

• Published in: Journal of Nuclear Medicine Vol. 58; no. 2; pp. 258 - 265
• Main Authors: Yang, Xue, Li, Jiao, Li, Xiaoyi, Liang, Zhiyong, Gao, Wen, Liang, Jun, Cheng, Shujun, Lin, Yansong
• Format: Journal Article
• Language: English
• Published: United States Society of Nuclear Medicine 01.02.2017
• Subjects: Adult; Biomarkers, Tumor - genetics; Carcinoma - epidemiology; Carcinoma - radiotherapy; Carcinoma - secondary; China - epidemiology; Correlation analysis; Female; Genetic Markers - genetics; Genetic Predisposition to Disease - epidemiology; Genetic Predisposition to Disease - genetics; Humans; Iodine Radioisotopes - therapeutic use; Male; Metastasis; Middle Aged; Mutation; Neoplasm Metastasis; Nuclear medicine; Prevalence; Promoter Regions, Genetic - genetics; Radiation Tolerance - genetics; Retrospective Studies; Telomerase - genetics; Thyroid cancer; Thyroid Neoplasms - epidemiology; Thyroid Neoplasms - radiotherapy; Treatment Failure; Treatment Outcome; differentiated thyroid carcinoma; radioactive iodine therapy; TERT mutation; therapy response

Telomerase reverse transcriptase (TERT) promoter mutation has been reported to be associated with aggressive characteristics in differentiated thyroid cancer (DTC). This study examined the status of TERT mutation in distant metastatic DTC and evaluated the correlation between TERT mutation and radio...